Investor Relations

NEO:CYBN

view stock
Cybin is a leading biotech company in the psychedelic therapeutic sector. Our team is focused on the development of mental healthcare treatment with a single-minded goal to dramatically improve patient outcomes versus currently available pharmacotherapies. Our work includes the development of new drug molecules, with a focus on optimizing treatment outcomes through: innovative drug delivery systems, concurrent therapy regimens, and technology-drive patient analytics. Learn more about how we are working to revolutionize mental healthcare in our three pillar strategy.
NEO:CYBN

view stock

Invest in Cybin

1

phase 2 trial in 2021

C$

120

M

raised to date to progress m&a strategy and clinical trials

14

patent filings

10

Patent filings

2

phase 1 trials in 2021

C$

88

M

raised to date to progress
m&a strategy

Investor Presentation

Last updated: 04.25.2021
Cybin Inc. Corporate Presentation
Download presentation

2021 Annual General Meeting

Download

2021 Financial Highlights and Business Update

Download

SEDAR Profile

Visit
Events
Date
Details
July 13, 2021
Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
August 12, 2021
Canaccord Genuity's 41st Annual Growth Conference
September 13, 2021
H.C. Wainwright 23rd Annual Global Investment Conference
Analyst Coverage
Charles C. Duncan
Elemer Piros
Patrick R. Trucchio
Sumant Kulkarni
Andrew Partheniou
Jason McCarthy
Nathan Weinstein

Cybin Inc. is followed by the analysts listed above. To the best of Cybin Inc.’s knowledge, the above list reflects all firms and analysts that publish research on Cybin Inc. and they have agreed to have their names included on the list above. Please note that any opinions, estimates or forecasts regarding Cybin Inc.’s performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of Cybin Inc. or its management. Cybin Inc. does not by its reference imply its endorsement of or concurrence with such information, conclusions or recommendations.

press releases
9.27.2021

Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences

Read more >
8.19.2021

Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

Read more >
8.17.2021

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion

Read more >
read more

Corporate Governance

close

Our site uses cookies. Learn more about our privacy policy.

I accept the use of cookies